| Products | Business Development | News | Contact |
|
||
Fcab™ : An antibody "compressed" into a much smaller format
Modular Antibody Technology is absolutely unique in delivering an alternative scaffold with full antibody properties and small size. Fcab™ (antigen binding Fc) is a highly innovative yet conservative protein engineering scaffold. It consists of the CH2 and CH3 domains of an antibody, naturally folded as a homodimer with a size of approximately 50kDa, with two identical antigen binding sites engineered into the CH3 domains.
Due to the localization of essential functional sites of antibodies in the CH2 and CH3 domains this molecule has the potential to offer antibody functionality:
- Long biological half-life
- Effector functions
- Protein A binding
- Two antigen-binding sites
In addition to antibody functionality, Fcab™ potentially offers the following advantages over antibodies: Fcab™
-
has a size of 50kDa (compared to 150kDa of a full antibody) which promises
- improved tissue penetration
- better efficacy on a molar basis and therefore
- reduced side effect potential as well as
- ease of manufacture -
can be produced in E.coli, yeast as well as mammalian cells depending on desired properties and
-
its effector functions may be tuned by a number of techniques, even be switched off by expression in a non-glycosylation production system such as E.coli.
-
may offer significant IP advantages in many cases by lacking variable regions, which may be claimed by third party antibody patents.
In a nutshell, the Fcab™ scaffold is a "compressed" version of an antibody with additional advantages like small size and a favourable IP situation.